|False-negative CA125 tests, time to diagnosis and stage in ovarian cancer: a cohort study using electronic records
Current UK guidance recommends that women presenting to primary care with symptoms of possible ovarian cancer be tested for the serum biomarker Cancer Antigen 125 (CA125). Yet, CA125 has never been evaluated in a primary care population and secondary care studies indicate that up to 20% of women with ovarian cancer have normal CA125 levels. It is possible that a false negative CA125 result could delay diagnosis. In this study we will use routinely collected primary care data and cancer registry data to determine the proportion of women with ovarian cancer who have normal and abnormal CA125 levels prior to diagnosis and explore associations between CA125 level and diagnostic intervals.
|Start date:||1st June 2018|
|End date:||20th March 2019|
|Contact person:||Dr Garth Funston|
|Contact Details:||Strangeways Research Laboratory
Telephone: (01223) 7n/a
|Further Information, References and Publications|